Laguna Bio
Clinical-stage biotechnology company developing engineered, highly attenuated live bacterial therapeutics to activate and expand innate T cell populations (γδ T cells, MAIT, NKT) for oncology and infectious/inflammatory disease indications. The company engineers microbial vectors for predictable in vivo PK/PD, performs preclinical validation in infection and cancer models, and has advanced an IND-cleared lead candidate into first-in-human studies.
Industries
Nr. of Employees
small (1-50)
Products
LGNA-100 (investigational)
First-in-class attenuated live bacterial immunotherapy derived from an engineered Listeria background, designed to expand and activate endogenous γδ T cells for treatment of high-risk leukemias post-hematopoietic stem cell transplant.
Pipeline programs (LGNA-200/300; LGNA-400+)
Preclinical and development-stage programs applying engineered microbial platforms to solid tumors (sarcoma, colorectal) and expanded indications including inflammatory and infectious diseases.
QUAIL Platform
The QUAIL platform is built on highly attenuated microbial vectors to activate a powerful innate immune response inside the body, targeting AML, other high-risk leukemias, and soft-tissue sarcomas by stimulating innate T cell populations and enhancing immune recognition.
IBIS Platform
The IBIS platform is an evolution of the QUAIL platform that directs innate T cells to specific tissues for precise targeting of tumor cells, while also activating and expanding endogenous innate T cells robustly and durably.
LGNA-100 (investigational)
First-in-class attenuated live bacterial immunotherapy derived from an engineered Listeria background, designed to expand and activate endogenous γδ T cells for treatment of high-risk leukemias post-hematopoietic stem cell transplant.
Pipeline programs (LGNA-200/300; LGNA-400+)
Preclinical and development-stage programs applying engineered microbial platforms to solid tumors (sarcoma, colorectal) and expanded indications including inflammatory and infectious diseases.
QUAIL Platform
The QUAIL platform is built on highly attenuated microbial vectors to activate a powerful innate immune response inside the body, targeting AML, other high-risk leukemias, and soft-tissue sarcomas by stimulating innate T cell populations and enhancing immune recognition.
IBIS Platform
The IBIS platform is an evolution of the QUAIL platform that directs innate T cells to specific tissues for precise targeting of tumor cells, while also activating and expanding endogenous innate T cells robustly and durably.
Expertise Areas
- Live bacterial therapeutics
- Innate-like T cell immunology (γδ T cells, MAIT, NKT)
- Microbial strain engineering and metabolic reprogramming
- Preclinical oncology and infectious disease models
Key Technologies
- Live-attenuated bacterial vectors
- Genetic engineering of bacteria
- Metabolic pathway engineering
- Microbial fermentation
News & Updates
FDA cleared the Investigational New Drug (IND) application for the lead candidate, enabling a Phase 1 first-in-human study.
Peer-reviewed preclinical study demonstrating engineered Listeria strains that produce riboflavin drive MAIT cell responses with efficacy in infectious disease and oncology models.
Peer-reviewed article describing genetic modifications to prevent extracellular growth and program MAIT cell activation via riboflavin synthesis in the QUAIL platform.
Announcements of planned presentations of preclinical data and platform mechanisms at AACR, Keystone Symposia, and other scientific meetings in 2025–2026.
FDA cleared the Investigational New Drug (IND) application for the lead candidate, enabling a Phase 1 first-in-human study.
Peer-reviewed preclinical study demonstrating engineered Listeria strains that produce riboflavin drive MAIT cell responses with efficacy in infectious disease and oncology models.
Peer-reviewed article describing genetic modifications to prevent extracellular growth and program MAIT cell activation via riboflavin synthesis in the QUAIL platform.
Announcements of planned presentations of preclinical data and platform mechanisms at AACR, Keystone Symposia, and other scientific meetings in 2025–2026.